Introduction
============

Behçet\'s disease (BD) is a systemic auto-inflammatory disorder principally characterized by recurrent oral aphthous ulcers, genital ulcers and ocular inflammation. BD also affects numerous other organs involved in the vascular, articular, gastrointestinal, pulmonary, and central nervous systems ([@b1-br-0-0-996]). As the prevalence of BD is high in certain regions of the world, including the Mediterranean, Middle East, Turkey and East Asia ([@b2-br-0-0-996]), previous studies have attempted to identify the etiopathogenic mechanisms underlying BD ([@b1-br-0-0-996],[@b2-br-0-0-996]); however, the causes and pathogenesis remain unclear.

B lymphocytes serve various functions, by acting as antigen-presenting cells to activate cluster of differentiation (CD)4^+^ T cells, by providing costimulatory molecules and cytokines, and by producing antibodies within the humoral immune system ([@b3-br-0-0-996]). B cells are also considered to serve a critical role in the pathogenesis of BD ([@b4-br-0-0-996]--[@b6-br-0-0-996]). Patients with active BD have been reported to exhibit elevated numbers of immunoglobulin (Ig)-secreting B cells, which are representative of fully differentiated B cells *in vivo* ([@b4-br-0-0-996]). Increased levels of activated and memory B cell subsets also suggests that alterations in B cell function may be involved in the development of BD ([@b5-br-0-0-996]). The role of B cell activating factor in signaling in B cells may contribute to B cell abnormalities and the development of skin lesions in patients with BD ([@b6-br-0-0-996]). Although studies have also evaluated the roles of T cells in BD ([@b7-br-0-0-996]--[@b9-br-0-0-996]), numerous other reports have continued to emerge regarding the contributions of abnormalities in B cell-associated factors, including CD43 ([@b10-br-0-0-996]--[@b13-br-0-0-996]), activation-induced cytidine deaminase (AID) ([@b14-br-0-0-996]--[@b19-br-0-0-996]), and interleukin (IL)-10 ([@b20-br-0-0-996]--[@b26-br-0-0-996]), to the progression of autoimmune disease.

CD43, also known as leukosialin or sialophorin, is a cell surface glycoprotein that is considered to be involved in the modulation of apoptosis, cell differentiation, immune homeostasis, cell adhesion, anti-adhesion and signal transduction ([@b10-br-0-0-996]). CD43 antigen is expressed on the majority of leukocytes, and in particular, is expressed on activated B and plasma cells, though not on resting (naïve) B cells. Abnormal expression of CD43 has been reported in a number of autoimmune pathologies, including systemic lupus erythematosus (SLE), Wiskott-Aldrich syndrome and human immunodeficiency virus infection ([@b11-br-0-0-996]--[@b13-br-0-0-996]).

From the perspective of humoral immunity, AID is proposed to be an important mechanistic factor that influences B cell function ([@b14-br-0-0-996]). AID deaminates target cytidines (C) to uracil\'s (U) in the Ig-encoding region and triggers U-G mismatches; through this mechanism, AID initiates Ig somatic hypermutation (SHM) and class switch recombination (CSR) ([@b14-br-0-0-996],[@b15-br-0-0-996]), resulting in the affinity maturation of antibodies and production of different Ig classes against pathogenic antigens ([@b15-br-0-0-996]). Thus, changes in AID expression have been associated with the severity of autoimmune diseases, including lupus nephritis and rheumatoid arthritis in mouse models ([@b16-br-0-0-996]--[@b19-br-0-0-996]).

Among the various subsets of B cells, some specific types negatively regulate the cellular immune response and inflammation ([@b20-br-0-0-996]). In particular, IL-10-producing subsets of regulatory B cells (BREGS), known as B10 cells, are now considered to serve major functions in the downregulation of autoimmunity, inflammation, and innate and adaptive immune responses, and are amongst the most intensively studied BREG subsets ([@b21-br-0-0-996]--[@b23-br-0-0-996]). IL-10 is an anti-inflammatory cytokine that is involved in the development and maintenance of immune tolerance and homeostasis ([@b24-br-0-0-996]), and suppresses proinflammatory cytokine production and antigen presentation ([@b25-br-0-0-996]). B10 cells not only limit inflammation and immune responses through the production of IL-10, but also facilitate the clearance of antigens by producing antigen-specific antibodies during the humoral immune response ([@b26-br-0-0-996]).

Accordingly, in the present study, the role of B cells in the pathogenesis of BD was investigated. In particular, the phenotypic proportions of B cells were assessed to determine their effects of the autoimmune system, and the expression of AID in B cells from patients with BD was evaluated for the first time *in vivo*. Additionally, the expression and plasma concentration of IL-10 were measured to provide insight into the effects of IL-10 and the roles of B10 cells in BD.

Materials and methods
=====================

### Patients and healthy controls (HCs)

A total of 16 Korean patients with BD (11 women and 5 men; mean age, 50.06±9.43) and 16 age- and sex-matched HCs were recruited from Konyang University Hospital (Daejeon, Republic of Korea). All participants provided informed consent for participation in the study. All patients with BD met the International Study Group Classification Criteria for BD ([@b27-br-0-0-996]) and received outpatient treatment. The clinical manifestations of the patients are presented in [Table I](#tI-br-0-0-996){ref-type="table"}. HCs were identified as having no history of autoimmune disease or other health problems following blood sample collection. The present study was approved by the Institutional Review Board of Konyang University Hospital (approval no.: KYUH 2016-12-015-002).

### Plasma and cell separation

Peripheral blood (\~8 ml) was obtained from each patient and HC by venipuncture using plastic blood collection tubes containing lithium heparin (BD Biosciences, San Jose, CA, USA). The samples were treated to separate B cells within 1 h at room temperature. An equivalent volume of phosphate-buffered saline (PBS) was added to the fresh blood samples, the samples were centrifuged for 15 min at 500 × g at room temperature, and the plasma supernatant was collected. The heparinized-plasma was then stored at −70°C until analysis by enzyme-linked immunosorbent assay (ELISA). After removing the remaining supernatant, corpuscles below the plasma were used to create a layer of peripheral blood mononuclear cells (PBMCs) by Histopaque density-gradient centrifugation (Sigma-Aldrich; Merck KGaA, Darmstadt, Germany) as previously described ([@b28-br-0-0-996]). The samples were then washed twice with Hank\'s balanced salt solution (Welgene, Inc., Daegu, Korea), and the acquired PBMCs were incubated for 30 min with CD19 microbeads (20 µl per 1×10^7^ cells; Miltenyi Biotec GmbH., Bergisch Gladbach, Germany) on ice. As CD19 is only expressed on B cells ([@b20-br-0-0-996]), magnetic-activated cell sorting (MACS) allowed us to positively select B cells by flow cytometric analysis using a FACS Calibur flow cytometer (BD Biosciences, San Jose, CA, USA) ([@b29-br-0-0-996]).

The lymphocyte and B cell numbers in the blood samples were evaluated at two time points: Immediately after layering of the PBMCs, and following the isolation of B cells by MACS sorting. Two independent researchers counted the number of cells twice using an inverted fluorescence microscope (CKX41; Olympus Corp., Tokyo, Japan).

### ELISA

The frozen plasma samples were used to measure the plasma levels of IL-10 and IgA. ELISA was performed with commercial ELISA kits \[IgA human simplestep ELISA kit (cat. no. ab196263; Abcam, Cambridge, UK) and high sensitivity human IL-10 ELISA kit (cat. no. D1000B, R&D Systems Inc., Minneapolis, MN, USA)\] according to the manufacturer\'s instructions.

### Flow cytometry analysis

Suspended B cells sorted using CD19 microbeads were washed with MACS buffer (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany) and then incubated with anti-human CD19-phycoerythrin (25--0199) and anti-human CD43-fluorescein isothiocyanate (FITC; 11-0439) antibodies (each 0.25 µg/5 µl; Affeymetrix; Thermo Fisher Scientific Inc., Waltham, MA, USA) for 30 min on ice. After washing twice with PBS, the cells were fixed with 1% paraformaldehyde at 4°C until use. The cells were analyzed with the FACSCalibur cytometer using CellQuest software, and the data were confirmed with FlowJo V10 (Tree Star, Inc., Ashland, OR, USA).

### RNA amplification and reverse transcription-quantitative polymerase chain reaction(RT-qPCR)

Total RNA was extracted from B cells using an RNAqueous-micro total RNA isolation kit (Invitrogen; Thermo Fisher Scientific, Inc.). The concentration and quality of the total RNA were assessed using an Optizen 3220 UV spectrophotometer (Rose Scientific Ltd., Edmonton, Canada). However, the quantities of isolated total RNA were inadequate, and thus mRNA was amplified after synthesizing cDNA from RNA samples with qualities of \>1.6 (absorbance 260/280) using a QuantiTect whole transcriptome kit (Qiagen, Inc., Valencia, CA, USA) to obtain a concentration of 100 ng/µl complementary DNA according to the manufacturer\'s instructions. For subsequent use, the amplified cDNA was diluted to 2 ng/µl in diethylpyrocarbonate (DEPC)-treated distilled H~2~O (Sigma-Aldrich; Merck KGaA). qPCR was performed in a final volume of 20 µl containing 2 µl diluted cDNA, 0.5 µl of 100 pmol/µl of each forward and reverse primer, 10 µl buffer (iQ SYBR-Green Supermix; Bio-Rad Laboratories, Inc., Hercules, CA, USA) and 7 µl DEPC-treated distilled H~2~O using a CFX96 touch real-time PCR detection 29 system (Bio-Rad Laboratories, Inc.). The primers used in the study were as follows: IL-10, forward, 5′-ACCTGGGTTGCCAAGCCTT-3′ and reverse, 5′-ATCGATGACAGCGCCGTAG-3′; AID, forward, 5′-CCTCTTGATGAACCGGAGGAA-3′ and reverse, 5′-AGCACTGTCACGCCTCTTCACT-3′; and glyceraldehyde 3-phosphate dehydrogenase (GAPDH), forward, 5′-ACAGTCAGCCGCATCTTCTT-3′ and reverse, 5′-ACGACCAAATCCGTTGACTC-3′. The qPCR conditions to amplify AID, IL-10 and GAPDH were as follows: Initial denaturation at 95°C for 3 min followed by 50 cycles of denaturation at 95°C for 10 sec, annealing for 10 sec at an appropriate temperature (56°C for IL-10 and GAPDH, 60°C for AID), and extension at 72°C for 10 sec. The targeted mRNA expression levels were quantified following normalization to the expression of GAPDH using the comparative threshold cycle (∆∆Cq) method ([@b30-br-0-0-996]).

### Statistical analysis

The data are presented as mean ± standard error of the mean unless otherwise stated. The significance of differences was determined by two-tailed paired Student\'s t tests, and differences with P\<0.05 were considered to indicate a statistically significant difference. All statistical analyses were performed with Excel 2013 (Microsoft Corp., Redmond, WA, USA).

Results
=======

### Plasma concentrations of IL-10 and IgA

IL-10 is an anti-inflammatory cytokine that inhibits the production of proinflammatory cytokines and serves a role in the development and maintenance of immune tolerance and homeostasis ([@b24-br-0-0-996],[@b25-br-0-0-996]). IgA is present at high levels at mucosal sites and is responsible for mucosal immunity ([@b31-br-0-0-996]); however, a number of patients with BD have been documented to have IgA nephropathy ([@b32-br-0-0-996]). Therefore, the present study measured the plasma levels of IL-10 and IgA by ELISA. The results indicated that the levels of IL-10 between patients with BD and HCs did not markedly differ (3.71±0.29 vs. 3.64±0.02, respectively; P=0.85; [Fig. 1A](#f1-br-0-0-996){ref-type="fig"}). Meanwhile, IgA levels were notably increased in patients with BD compared with HCs; however, the difference was not significant (2.28±0.24 vs. 1.69±0.20, respectively; P=0.068; [Fig. 1B](#f1-br-0-0-996){ref-type="fig"}).

### CD43^+^CD19^+^ B cell count is indistinguishable between patients with BD and HCs

Lymphocyte and B cell numbers were slightly reduced in the PBMC populations of patients with BD compared with those in HCs, and the percentage of B cells to lymphocytes was markedly lower in patients with BD; however, the differences were not significant ([Table II](#tII-br-0-0-996){ref-type="table"}). CD19^+^ B cells were isolated to \~97% purity ([Fig. 2A](#f2-br-0-0-996){ref-type="fig"}) from the human PBMCs and anti-human CD43-FITC antibodies were used to determine changes in the activated (CD43^+^CD19^+^) ([@b33-br-0-0-996]) B cell population by flow cytometry analysis. Despite the reduction in the B cell percentage, the number of CD43^+^CD19^+^ B cells in patients with BD did not differ significantly compared with that in HCs (2.41±0.57 vs. 2.29±0.31, respectively; P=0.86; [Fig. 2B](#f2-br-0-0-996){ref-type="fig"}). This result corresponds to a previous report that observed no marked alteration in the CD43^+^ B cell component of patients with SLE compared with healthy donors ([@b34-br-0-0-996]).

### Expression of IL-10 and AID mRNA in B cells

To further investigate abnormalities that may affect the etiopathology of BD, the expression of IL-10 and AID mRNA was evaluated. The results indicated that the mRNA levels of IL-10 were significantly downregulated in patients with BD compared with those in HCs (0.49±0.12 vs. 1.08±0.26, respectively; P=0.03; [Fig. 3A](#f3-br-0-0-996){ref-type="fig"}). Meanwhile, the levels of AID mRNA were significantly increased in patients with BD compared with those in HCs (10.27±2.72 vs. 1.04±0.12, respectively; P=0.003; [Fig. 3B](#f3-br-0-0-996){ref-type="fig"}). These results were consistent with previous studies suggesting that high expression of AID triggers autoimmune disease in lupus-prone mice ([@b18-br-0-0-996]) and that abnormal AID expression contributes to autoimmune diseases ([@b35-br-0-0-996]).

Discussion
==========

The objective of the present study was to investigate changes in B cells in patients with BD. Specifically, phenotypic analysis was conducted by comparing CD43^+^ populations among patients with BD and HCs. Although the number of CD43^+^CD19^+^ B cells did not differ between patients with BD and HCs, it was observed, to the best of our knowledge for the first time, that the expression of IL-10 mRNA in B cells was significantly decreased in patients with BD compared with HCs. Furthermore, AID mRNA levels in B cells were increased by \~10-fold in patients with BD compared with those in HCs.

To date, studies of AID, as a factor involved in immunity, have demonstrated that this protein can induce autoantibody production ([@b16-br-0-0-996]--[@b19-br-0-0-996]). A study by Hsu *et al* ([@b16-br-0-0-996]) reported that BXD2 mice, presenting with age-related development and progression of arthritis, glomerulonephritis and high immune complex titers, exhibited significant alterations in autoantibody production and AID expression in the germinal center when compared with wild-type mice. Murphy roths large (MRL) mice, which present SLE-like symptoms, also exhibit increased AID expression, and hyperactivity of SHM and CSR when focusing on heavy mutations in the Ig locus ([@b18-br-0-0-996]). Additionally, in AID-knockdown and AID-knockout MRL mice, lupus nephritis, as a main condition triggered by autoantibodies, was alleviated compared with AID wild-type MRL mice ([@b17-br-0-0-996],[@b19-br-0-0-996]). Furthermore, AID may account for the antibody-independent role of B cells in T cell activation and autoimmunity ([@b36-br-0-0-996]). In the present study, it was observed that AID mRNA expression was markedly increased in patients with BD patient compared with HCs. Although the majority of previous studies have been performed in mice, the indicated effects of autoantibodies may also be relevant in the pathogenesis of BD in humans. However, the specific underlying mechanisms remain unclear, and additional studies are required to determine the exact relationship between AID and BD. Specifically, to elucidate the effect of aberrant AID expression on Ig CSR and SHM in B cells in BD, the expression patterns and functional roles of AID splicing variants should be examined in BD B cells, as AID splicing variants have been indicated to serve various functions in Ig CSR and SHM ([@b37-br-0-0-996]).

BREGS are involved in immunomodulation and suppression of the immune response through a range of mechanisms. The roles of BREGS have been studied in mouse models of autoimmune diseases including SLE ([@b38-br-0-0-996]) and experimental autoimmune encephalomyelitis ([@b21-br-0-0-996]). However, there is no clear understanding of the characteristics of BREGS ([@b39-br-0-0-996]). Three mature B cell subsets have been identified in mice \[B1 cells, follicular B (FOB) cells, marginal zone B (MZB) cells\]; these subsets have different characteristics regarding their phenotypes and functional activities ([@b40-br-0-0-996]). In particular, FOB cells, also known as adaptive B cells, and MZB cells belong to a subset of innate-like B (ILB) cells termed B2 cells. These B2 cells contribute to the adaptive immune response and mediate humoral immunity; they may also produce high-affinity antibodies and generate immunological memory ([@b41-br-0-0-996]). Human B1 cells are typically considered as CD43^+^ B cells, while B2 cells may be regarded as CD43^−^ B cells ([@b34-br-0-0-996]). Furthermore, CD43^−^ IL-10-producing ILB cells have been identified to have BREG activity in immune responses during chlamydia infection ([@b42-br-0-0-996]). In the present study, IL-10 mRNA expression was reduced in the B cells of patients with BD, suggesting that the percentage of CD43- IL-10-producing B cells may be reduced in BD, as these cells have more potential than CD43^+^ IL-10-producing B cells to affect the immune system. However, only the whole CD43^−^ B cell was distinguished from the whole CD43^+^ B cell proportion; therefore, further studies are necessary to clarify the involvement of IL-10-producing subtypes in BD. Meanwhile, in contrast to IL-10 mRNA levels, plasma IL-10 levels were not altered. This result may be explained by the observation that T cells and neutrophils also produce IL-10 ([@b43-br-0-0-996],[@b44-br-0-0-996]). In addition, the change in IL-10 level may not be reflected in the plasma as the proportion of total B cells in the peripheral blood is relatively low (\~10%) ([@b45-br-0-0-996]).

There were a number of limitations to the present study. Firstly, the patients were not grouped according to the status of BD (active vs. inactive). Due to the experimental methods used in the study, fresh blood samples were required from patients, and blood was drawn from patients immediately following their visit to the hospital. However, it was not possible to request that patients visit the hospital specifically when they had symptoms. Thus, the majority of the patients were evaluated during the inactive disease period, and only three patients presented with active BD during evaluation. Secondly, all the patients with BD were treated with medication at the time of blood sampling. This may have affected the results of serum cytokine analysis and RT-qPCR. Therefore, further studies are required with improved control of patient treatment and blood sample collection in order to obtain results of higher accuracy.

In conclusion, the present study described the concentrations of IL-10 and IgA in plasma, the number of CD43^+^/CD43^−^ B cells and the mRNA levels of IL-10 and AID in B cells from fresh peripheral blood samples of patients with BD and matched HCs. The present findings indicated, to the best of our knowledge for the first time, that AID mRNA was upregulated in patients with BD. These data may be a starting point for examining the mechanisms and influence of AID in BD in further studies. Correlations between disease severity and AID expression should also be evaluated, which may implicate the applications of AID in the diagnosis or treatment of BD. Furthermore, based on the present results that IL-10 mRNA was downregulated in B cells *in vivo*, future studies should be performed to analyze B10 cells, which downregulate immune responses, to elucidate the immunological mechanisms involved in BD.
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![Plasma concentrations of IL-10 and IgA. The plasma levels of (A) IL-10 and (B) IgA were determined using ELISA for samples from patients with BD (n=16) and age- and sex-matched HCs (n=16). BD, Behçet\'s disease; HCs, healthy controls; IL-10, interleukin-10; IgA, immunoglobulin A.](br-07-06-0520-g00){#f1-br-0-0-996}

![Frequencies of CD43^+^CD19^+^ cells in BD patients and HCs. CD19^+^ cells were purified from the peripheral blood mononuclear cell populations of patients with BD (n=16) and HCs (n=16). (A) Representative histograms of the CD43^+^ expression rate in CD19^+^ B cells, as determined by FlowJo analysis. (B) CD43^+^CD19^+^ cell percentage. The box plots represent the medians, interquartile ranges, standard errors and highest/lowest values. BD, Behçet\'s disease; HCs, healthy controls; CD, cluster of differentiation.](br-07-06-0520-g01){#f2-br-0-0-996}

![Changes in the expression of IL-10 and AID mRNA in CD19^+^ B cells. RNAs were isolated from purified CD19^+^ B cells of patients with BD and HCs (n=11 per group; 5 patient samples were excluded from RNA amplification due to low RNA quality), and the levels of (A) IL-10 and (B) AID mRNA were measured using RT-qPCR. All data are represented as a fold-change using GAPDH as a control. \*P\<0.05, \*\*P\<0.01. AID, activation-induced cytidine deaminase; IL-10, interleukin-10; BD, Behçet\'s disease; HCs, healthy controls; RT-qPCR, reverse transcription-quantitative polymerase chain reaction.](br-07-06-0520-g02){#f3-br-0-0-996}

###### 

Clinical manifestations of patients with Behçet\'s disease.

  Case                                             Sex/age (years)   Oral ulcer     Genital ulcers   Skin lesions   Eye lesions                      Thrombosis   Arthritis   Vasculitis   ESR (mm/h)   CRP (mg/l)
  ------------------------------------------------ ----------------- -------------- ---------------- -------------- -------------------------------- ------------ ----------- ------------ ------------ ------------
  1                                                F/57              AU/DU/Mul/PL   Y                EN/PF          Uveitis                          Y            Y           Y            11           0.2
  2^[a](#tfn2-br-0-0-996){ref-type="table-fn"}^    F/55              AU/DU/Mul/PL   Y                EN             Uveitis, conjunctivitis          N            Y           Y            68           3.0
  3^[a](#tfn2-br-0-0-996){ref-type="table-fn"}^    M/52              AU             Y                EN             Conjunctivitis                   N            Y           Y            15           0.1
  4^[a](#tfn2-br-0-0-996){ref-type="table-fn"}^    M/25              AU/Mul         Y                EN             Uveitis                          N            N           Y            16           0.2
  5                                                F/50              AU/Mul         N                EN             --                               N            N           Y            16           0.1
  6                                                F/47              AU/Mul         Y                EN             Conjunctivitis                   N            Y           N            29           0.1
  7^[a](#tfn2-br-0-0-996){ref-type="table-fn"}^    M/43              DU/S           N                EN             Uveitis                          N            N           N              5          0.1
  8                                                F/61              AU/DU/Mul      Y                EN             --                               N            N           Y            15           0.3
  9                                                M/48              DU/            Y                EN             --                               N            N           N              7          0.1
  10                                               M/53              AU/DU/Mul      Y                EN/PF          Uveitis                          N            N           N            44           3.1
  11                                               F/50              AU             Y                --             --                               N            N           N            12           0.1
  12                                               F/38              AU/Mul/PL      Y                EN             Uveitis                          N            Y           N            45           4.0
  13                                               F/49              DU             Y                EN/PF          Uveitis                          N            N           N              9          0.9
  14                                               F/59              AU/DU          Y                EN             --                               N            N           N            24           0.1
  15                                               F/55              AU/DU/Mul      Y                EN             --                               N            N           N            39           1.4
  16^[a](#tfn2-br-0-0-996){ref-type="table-fn"}^   F/38              AU/DU/Mul      Y                EN             Conjunctivitis, optic neuritis   N            N           N            10           2.7

Patient numbers were assigned according to the chronological order of hospital visitation.

Samples excluded from RNA amplification due to low RNA quality. AU, aphthae ulcer; DU, deep ulcer; Mul, multiple; S, single; PL, posterior location; EN, erythema nodosum; PF, pseudofolliculitis; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; Y, present; N, not present; M, male; F, female.

###### 

Comparisons of B cell and lymphocyte counts between patients with BD and HCs.

  Cell type                 BD          HC           P-value^[a](#tfn4-br-0-0-996){ref-type="table-fn"}^
  ------------------------- ----------- ------------ -----------------------------------------------------
  Lymphocytes (×10^5^/ml)   7.02±0.85   7.76±0.72    0.51
  B cells (×10^4^/ml)       7.24±1.52   9.60±1.07    0.21
  B cells/lymphocytes (%)   9.43±1.34   12.61±1.15   0.08

Data are presented as means ± standard error of the mean.

Two-tailed paired Student\'s t-tests were used for the comparisons between patients with BD and HCs. BD, Behçet disease; HC, healthy control.
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